Get the app
US › Healthcare

Adicet Bio Inc (ACET)

US · Healthcare · Biotechnology

$3.05+4.45%
Last close · 2026-11-06

Latest quarter · ended 2026-09-30

Net profit
$-18.9M
EPS
$-1.76
EPS estimate
$-1.56

EPS came in at -1.76 against a street estimate of -1.56 — a miss of 12.8%.

Key statistics

Market cap
$27.3M
Forward P/E
0.0
P/B
0.25
Book value
$11.16
EPS (TTM)
$-9.92
52-week high
$11.20
52-week low
$2.87
50-day MA
$6.79
200-day MA
$7.62
Beta
1.74

Analyst view

Analysts rate Adicet Bio Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $34.83.

Shareholding

Insiders
6.44%
Institutions
65.83%

Largest institutional holders

FundStake
RA Capital Management, LLC9.96%
Orbimed Advisors LLC9.02%
Franklin Templeton Inc6.69%
Citadel Advisors Llc4.62%
Vanguard Capital Management, LLC3.67%
Adage Capital Partners Gp LLC2.93%
Renaissance Technologies Corp2.84%
Stonepine Capital Management Llc2.62%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Adicet Bio Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-11-07.